Stockscreener 앱 받기
30.57
0.46%
-0.14
Tg Therapeutics Inc 주식(TGTX)의 최신 뉴스
Moving Averages: Should you avoid TG Therapeutics Inc stock right nowJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Goldman Sachs Raises Price Target for TG Therapeutics (TGTX) to $39 | TGTX Stock News - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Trading 7.5% HigherHere's Why - MarketBeat
TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) - Seeking Alpha
HC Wainwright Forecasts TG Therapeutics FY2025 Earnings - MarketBeat
TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook - The Globe and Mail
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries - Intellectia AI
TG Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - MarketBeat
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Mom - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpTime to Buy? - MarketBeat
TGTX Stock Surges Over 12% Amid Positive Market Movement - GuruFocus
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities - The Globe and Mail
TG Therapeutics shares hit highest since November, last up 12.9% after prelim 2025 sales top estimate - marketscreener.com
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? - Asianet Newsable
Why TG Therapeutics Stock Is Moving Today - Benzinga
TG Therapeutics steigert Umsatzprognose für 2026 und übertrifft Umsatzprognose für 2025 - TradingView — Track All Markets
TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat - TradingView — Track All Markets
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED) - Benzinga
In the Wake of TG Therapeutics, Inc.'s (NASDAQ:TGTX) Latest US$225m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
Avoiding Lag: Real-Time Signals in (TGTX) Movement - Stock Traders Daily
SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Menafn
Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday - Benzinga
TG Therapeutics reports $616 million in preliminary 2025 revenue By Investing.com - Investing.com Nigeria
TG Therapeutics Stock Pre-Market (+7.0%) : Strong 2026 Revenue Guidance Issued - Trefis
TG Therapeutics Looks To ENHANCE Growth With Pivotal 2026 Trial Readout - RTTNews
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally - Stocktwits
TG Therapeutics (TGTX) Projects Strong Revenue Growth for 2026 - GuruFocus
TGTX Sets 2026 Expense Forecast Amid New Developments - GuruFocus
TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26 - Intellectia AI
TG Therapeutics jumps after preliminary 2025 sales exceed forecast - TradingView — Track All Markets
TG Therapeutics provides preliminary fourth quarter and full year 2025 results - marketscreener.com
Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results - TradingView — Track All Markets
TG Therapeutics Stock Climbs After The Bell: Here's Why - Benzinga
TGTX Expects Strong Revenue Growth Driven by Briumvi Success - GuruFocus
TG Therapeutics Issues 2026 Revenue Outlook; Shares Rise After Hours - marketscreener.com
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones - The Manila Times
TG Therapeutics stock rises after strong 2025 revenue and positive 2026 outlook - Investing.com Canada
TG Therapeutics reports $616 million in preliminary 2025 revenue - Investing.com
MS drug maker TG Therapeutics targets $900M in 2026 sales, trial data ahead - Stock Titan
Notable Tuesday Option Activity: TGTX, SPOT, TECH - Nasdaq
Is TG Therapeutics' (TGTX) JPM Briumvi Update Quietly Reframing Its MS Commercial Narrative? - Sahm
Aug PostEarnings: Is TG Therapeutics Inc still a buy after recent gains2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Gem With 56.56% Upside Potential - DirectorsTalk Interviews
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX - TechStock²
Market Leaders: Why TG Therapeutics Inc. stock is in analyst buy zone2025 Major Catalysts & Proven Capital Preservation Methods - Улправда
TG Therapeutics (NASDAQ:TGTX) Stock Price Down 5.4%Here's Why - MarketBeat
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next - TechStock²
How TG Therapeutics Inc. stock performs in stagflationDividend Hike & Target Return Focused Picks - Улправда
Will TG Therapeutics Inc. (NKB2) stock outperform global peers2025 Earnings Surprises & Low Risk Investment Opportunities - Улправда
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
TG Therapeutics, Inc. (TGTX) Stock Analysis: Strong Buy Ratings and 51.25% Upside Potential - DirectorsTalk Interviews
Is TG Therapeutics Inc a good long term investmentBear Market Strategies & Follow Top Performers in the Community - earlytimes.in
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
4.73%
0.92%
자본화:
|
볼륨(24시간):